๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat

โœ Scribed by J. Tarning; N. Lindegardh; S. Sandberg; N.J.P. Day; N.J. White; M. Ashton


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
173 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

โœฆ Synopsis


This study aimed to evaluate the pharmacokinetic properties of piperaquine in the rat after intravenous and oral administration, and to identify and characterize the main piperaquine metabolites in rat plasma, urine, faeces and bile after intravenous administration. Male Sprague-Dawley rats were administered piperaquine as an emulsion orally or as a short-term intravenous infusion. Venous blood for pharmacokinetic evaluation was frequently withdrawn up to 90 h after dose. Urine, bile and faeces were collected after an infusion in rats kept in metabolic cages or in anesthetized rats. Pharmacokinetic characterization was done by compartmental modeling and non-compartmental analysis using WinNonlin. Piperaquine disposition was best described by a 3-compartment model with a rapid initial distribution phase after intravenous administration. The pharmacokinetics of piperaquine was characterized by a low clearance, a large volume of distribution and a long terminal half-life. Piperaquine displayed a low biliary clearance and less than 1% of the total dose was recovered in urine. The absolute oral bioavailability was approximately 50%. The main metabolite after intravenous administration of piperaquine was a carboxylic acid product identical to that reported in humans. The similarity with results in humans indicates the rat to be a suitable species for nonclinical in vivo piperaquine studies.


๐Ÿ“œ SIMILAR VOLUMES


Pharmacokinetics of deramciclane in dogs
โœ Harri Kanerva; Hannele Huuskonen; Anneli Alhonen-Raatesalmi; Timo Nevalainen; Ar ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 204 KB ๐Ÿ‘ 2 views

The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der

Pharmacokinetics of ethopropazine in the
โœ Mojdeh Maboudian-Esfahani; Dion R. Brocks ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB ๐Ÿ‘ 2 views

The pharmacokinetics of the anticholinergic drug ethopropazine (ET) have been studied in the rat after intravenous (i.v.) and oral administration. After i.v. doses of 5 and 10 mg/kg ET HCl, mean +/- S.D. plasma AUC were 9836 +/- 2129 (n = 4 rats) and 13096 +/- 4186 ng h/mL (n = 5 rats), respectively

Pharmacokinetics of ฮฑ-dihydroergocriptin
โœ G. Coppi; S. Silingardi ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 440 KB ๐Ÿ‘ 2 views

The pharmacokinetics of a-dihydroergocriptine methane sulphonate in rats were investigated using an HPLC method for the detection of unchanged adihydroergocriptine (DHEK) in plasma, organs (kidneys, heart, lungs, spleen, liver, and brain), and urine. The plasma profile of DHEK obtained after intrave